Nuvectis Pharma, Inc. NVCT
21.08 USD +0.06 (+0.29%)
At closeNov 10, 2026, 4:01 PM EST
21.08 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
20.23 Day range 21.30
5.77 52-week range 29.28
- YTD
- +179.21%
- 1 year
- +247.28%
News
seekingalpha.com Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript
marketbeat.com Nuvectis Pharma Q3 Earnings Call Highlights Nuvectis Pharma NASDAQ: NVCT said its third quarter marked a strategic shift into late-stage development following a licensing agreement with Haisco for ex-China rights to two drug candidates:…
benzinga.com Nuvectis Pharma Q3 2026 Earnings Call Transcript Nuvectis Pharma (NASDAQ:NVCT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Nuvectis Pharma Q3 EPS $(1.02) Misses $(0.24) Estimate Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(0.24) by 325 percent. This is a 131.82 percent decrease over losses of…
globenewswire.com Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company.…
globenewswire.com Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 Fort Lee, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative…- benzinga.com Nuvectis Pharma Reports Data From Its Phase 1b Trial Of NXP200 Demonstrates Objective Response Rate Based On Response Assessment In Neuro-Oncology Criteria 2.0 Of 40%; Deep Responses Were 87.5% Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of…
globenewswire.com Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas Single-agent NXP200 was administered to 27 patients with recurrent or progressive gliomas (20 with high-grade and 7 with low-grade). The objective response rate (ORR) based on Response Assessment in…
defenseworld.net Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up – What’s Next? Nuvectis Pharma, Inc. (NASDAQ: NVCT - Get Free Report)'s stock price gapped up prior to trading on Monday. The stock had previously closed at $20.13, but opened at $21.12. Nuvectis Pharma shares last…
globenewswire.com Nuvectis Pharma to Participate in the Maxim Growth Summit 2026 Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of…
defenseworld.net Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25 According to Brokerages Shares of Nuvectis Pharma, Inc. (NASDAQ: NVCT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five research firms that are presently covering the company,…
benzinga.com HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $39 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $39 price target.
benzinga.com Nuvectis Pharma's NXP200 BRAF Inhibitor Receives China's Breakthrough Therapy Designation Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of…
globenewswire.com Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma Fort Lee, NJ, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of…
benzinga.com This Cal-Maine Foods Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday Analysts downgraded UiPath, Cal-Maine with several price-target cuts.
defenseworld.net BlackRock Inc. Acquires New Stake in Nuvectis Pharma, Inc. $NVCT BlackRock Inc. bought a new position in shares of Nuvectis Pharma, Inc. (NASDAQ: NVCT) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The…
globenewswire.com Nuvectis Pharma To Participate in Upcoming Investor Conferences Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of…
benzinga.com This Toast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday Wall Street analysts changed outlook on top companies. Check out complete rating changes, including upgrades/downgrades, on our page.
benzinga.com This PG&E Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Sempra Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Deere Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This SolarEdge Analyst Turns Bullish; Here Are Top 2 Upgrades For Wednesday Wall Street analysts upgraded DTM, SEDG. Check out analyst ratings and price targets on Benzinga.
benzinga.com This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday Top names on Wall Street have had their outlook changed by analysts, including downgrades and price target cuts. See what they think about EIX.- benzinga.com This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Consider ACMR stock: analysts' thoughts
benzinga.com This Five Below Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Top Wall Street analysts changed outlook on top names. See analyst ratings for VTEX, FIS, and more. FIS stock analysis also included.
benzinga.com This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Top analysts upgraded Fluence Energy, Dynatrace, and Advanced Micro Devices, Check out their ratings.
benzinga.com This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.
benzinga.com This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday Top Wall Street analysts changed their outlook on top names. See analyst ratings page for full list. DRI, JANX, and more mentioned.
benzinga.com This Domino's Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday Analysts changed outlook on top names like BRCB, CMG and more. See ratings page for full list. CMG stock: analysts' views.
benzinga.com This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts change outlook on top names. For full ratings, including upgrades and downgrades, see analyst ratings page.
benzinga.com Cantor Fitzgerald Initiates Coverage On Nuvectis Pharma with Overweight Rating Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Nuvectis Pharma (NASDAQ:NVCT) with a Overweight rating.
zacks.com Nuvectis Stock Surges Around 97% in 3 Months: Here's Why NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.
globenewswire.com Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights FORT LEE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of…
zacks.com Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 56.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among…
globenewswire.com Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors First global approval of a once-daily, orally administered, Complement Factor B inhibitor Approval based on robust efficacy and safety data from Haisco's broad completed clinical development program…
globenewswire.com Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative…
benzinga.com Ryanair Posts Weak Q1 Results, Joins HDFC Bank And Other Big Stocks Moving Lower In Monday’s Pre-Market Session US stock futures higher with Nasdaq 100 up 150 points. Ryanair (RYAAY) shares fall after weak Q1 results. Other stocks declining in pre-market.
newsfilecorp.com StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco…
zacks.com Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
benzinga.com IBM To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all rating changes, see analyst ratings page.
zacks.com What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now? Does Nuvectis Pharma, Inc. (NVCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Abivax (NASDAQ:ABVX) shares increased by 36.0% to $130.74 during Tuesday's pre-market session. The company's market cap stands at $7.6 billion. Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares…
benzinga.com Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session US stock futures up, Dow futures gain 100+ points. Concentrix Corp (CNXC) shares down 24% after weak Q2 results and lowered FY26 guidance. Other stocks also decline in pre-market trading.
benzinga.com Why AeroVironment Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket AeroVironment, Inc. (NASDAQ: AVAV) jumped 21.4% in pre-market trading after reporting strong financial results for fiscal Q4 and guidance for 2027.
globenewswire.com Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market session. The market value of their outstanding shares is at $74.6 million. BNB Plus (NASDAQ:BNBX) stock…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's regular session. The market value of their outstanding shares is at $22.1 million. Icecure Medical…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session